<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03287076</url>
  </required_header>
  <id_info>
    <org_study_id>NTA1127</org_study_id>
    <secondary_id>2018-004325-88</secondary_id>
    <nct_id>NCT03287076</nct_id>
  </id_info>
  <brief_title>Trial of EXenatide in Acute Ischaemic Stroke</brief_title>
  <acronym>TEXAIS</acronym>
  <official_title>A Multicentre, Randomised Controlled Trial of Exenatide Versus Standard Care in Acute Ischemic Stroke (TEXAIS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neuroscience Trials Australia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Health and Medical Research Council, Australia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Monash University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Neuroscience Trials Australia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multicentre, randomised controlled Trial of Exenatide versus standard care in Acute&#xD;
      Ischemic Stroke&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Overview: Elevated blood glucose levels are common in many acute diseases, resulting in worse&#xD;
      clinical outcomes. Hyperglycaemia in acute ischaemic stroke (post-stroke hyperglycaemia&#xD;
      [PSH]) occurs in up to 50% patients, reduces the efficacy of stroke thrombolysis with&#xD;
      increased risk of haemorrhage, increases infarct size, and results in worse clinical outcomes&#xD;
      and death. Insulin-based therapies have not proved beneficial in treating PSH: they are&#xD;
      difficult to implement and maintain, cause frequent hypoglycaemia, may cause increased&#xD;
      infarct size, and do not reduce mortality or improve clinical outcomes. An alternative,&#xD;
      simple to use, treatment for PSH may therefore have a significant impact not only for acute&#xD;
      stroke care, but in other acute diseases.&#xD;
&#xD;
      Pilot data: Exenatide is a commonly used diabetes drug (a synthetic glucagon- like peptide-1&#xD;
      receptor agonist) that increases insulin secretion. Importantly, this action is glucose&#xD;
      dependent - as blood glucose levels decrease, its stimulatory effect on insulin secretion&#xD;
      subsides, with a very low risk of hypoglycaemia. A small randomised pilot study of 17&#xD;
      consecutive, unselected patients (ie. regardless of their admission glucose level) with acute&#xD;
      ischaemic stroke compared subcutaneous exenatide 5μg for 5 days with routine standard of&#xD;
      care. Overall, blood glucose levels remained consistently lower (and less variable) in the&#xD;
      exenatide group, and most noticeably in those stroke patients with known diabetes. Exenatide&#xD;
      was safe and well tolerated by all patients, with no symptomatic hypoglycaemia.&#xD;
&#xD;
      Trial design: TEXAIS is a 3 year Phase 2, multi centre, prospective, randomised, open label,&#xD;
      blinded end-point (PROBE) trial comparing Exenatide to Standard of Care. The sample size is&#xD;
      528 patients (264 in each arm).&#xD;
&#xD;
      Intervention: Treatment arm will receive Exenatide (Byetta) 5μg subcutaneously twice daily&#xD;
      for five days, commencing within 9 hours of symptom onset. Stroke onset time for wake-up&#xD;
      strokes is taken as mid-point between going to bed, and waking up. Antiemetic therapy&#xD;
      (metoclopramide or ondansetron) will be commenced with the first dose of Exenatide. In&#xD;
      patients receiving tPA, Exenatide will be given alongside, or as soon as possible, following&#xD;
      tPA administration (within 60 minutes). Diabetic patients already on oral agents and/or&#xD;
      insulin may continue these (as per standard practice) in addition to Exenatide. Continuous&#xD;
      glucose monitors (CGMs) will track the intra-day dynamic variability of glucose in acute&#xD;
      stroke.&#xD;
&#xD;
      Translation: TEXAIS is a simple, practical, study that can enrol all patients with ischaemic&#xD;
      stroke, regardless of admission blood glucose level, regardless of stroke severity, with no&#xD;
      target glucose level, and with low risk of hypoglycaemia.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 23, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 4, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>improved neurological outcome</measure>
    <time_frame>7 days</time_frame>
    <description>Treatment with short acting Exenatide (Byetta) in patients with acute ischaemic stroke is hypothesised to improve neurological outcome as measured by ≥8 point improvement in the National Institutes of Health Stroke Scale (NIHSS) stroke disability score (or NIHSS 0-1) at 7 days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>post stroke hyperglycaemia</measure>
    <time_frame>90 days</time_frame>
    <description>reduce the occurrence of post stroke hyperglycaemia (&gt;7mmol/l).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Rankin Scale</measure>
    <time_frame>90 days</time_frame>
    <description>improve Modified Rankin Scale (mRS) at 90 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NIHSS</measure>
    <time_frame>90 days</time_frame>
    <description>improve NIHSS at 90 days</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">350</enrollment>
  <condition>Acute Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive exenatide injections</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard care for stroke as per hospital protocol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exenatide Injection</intervention_name>
    <description>5μg subcutaneously twice daily for five days, commencing within 9 hours of symptom onset</description>
    <arm_group_label>Active</arm_group_label>
    <other_name>Byetta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males and females 18 years or older&#xD;
&#xD;
          -  Acute Ischaemic Stroke - CT brain exclusion of haemorrhagic stroke&#xD;
&#xD;
          -  Blood glucose level on admission ≥ 4mmol/L&#xD;
&#xD;
          -  First trial treatment possible within 9 hours of stroke onset&#xD;
&#xD;
          -  Pre-morbid /mRS score of 0-2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Haemorrhagic stroke&#xD;
&#xD;
          -  Poor clinical prognosis /palliation (considered unlikely to survive beyond 14 days&#xD;
             post stroke).&#xD;
&#xD;
          -  Any known allergy or hypersensitivity to Exenatide&#xD;
&#xD;
          -  Females who are pregnant (known or suspected) or currently breastfeeding&#xD;
&#xD;
          -  Any past history of pancreatitis or evidence of active pancreatitis&#xD;
&#xD;
          -  History of active severe gastrointestinal disease (including but not limited to&#xD;
             gastroparesis and dumping syndrome)&#xD;
&#xD;
          -  Current chronic kidney disease stage 4 or 5 (creatinine clearance &lt;30ml/min)&#xD;
&#xD;
          -  Current participation in another interventional clinical trial&#xD;
&#xD;
          -  Inability to provide consent (participant or person responsible as local laws apply)&#xD;
&#xD;
          -  Current use of Exenatide (Byetta®), or other GLP-1 agonist diabetes medication&#xD;
&#xD;
          -  Patients considered unlikely to be able to be followed up at 3 months (including but&#xD;
             not limited to geographical location of patient at 3 months)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher Bladin</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Florey Institute of Neuroscience &amp; Mental Health Melbourne Brain Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St Vincent's Hospital Sydney</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liverpool Hospital</name>
      <address>
        <city>Liverpool</city>
        <state>New South Wales</state>
        <zip>2170</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunshine Coast University Hospital</name>
      <address>
        <city>Birtinya</city>
        <state>Queensland</state>
        <zip>4575</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane and Women's Hospital</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital</name>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Launceston General Hospital</name>
      <address>
        <city>Launceston</city>
        <state>Tasmania</state>
        <zip>7250</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Box Hill Hospital</name>
      <address>
        <city>Box Hill</city>
        <state>Victoria</state>
        <zip>3128</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Vincent's Hospital Melbourne</name>
      <address>
        <city>Fitzroy</city>
        <state>Victoria</state>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Hospital</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St John of God Midland Public &amp; Private Hospital</name>
      <address>
        <city>Midland</city>
        <state>Western Australia</state>
        <zip>6056</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fiona Stanley Hospital</name>
      <address>
        <city>Murdoch</city>
        <state>Western Australia</state>
        <zip>6150</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helsinki University Hospital</name>
      <address>
        <city>Helsinki</city>
        <zip>00290</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CDHB Christchurch Hospital</name>
      <address>
        <city>Christchurch</city>
        <zip>8140</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Finland</country>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 13, 2017</study_first_submitted>
  <study_first_submitted_qc>September 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 19, 2017</study_first_posted>
  <last_update_submitted>September 7, 2021</last_update_submitted>
  <last_update_submitted_qc>September 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stroke</keyword>
  <keyword>glucose</keyword>
  <keyword>exenatide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Exenatide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

